fibrosis
Sep 04, 2024
Nonalcoholic Steatohepatitis (NASH): A Growing Epidemic
Obesity and diabetes are a global epidemic contributing to an increasing prevalence of related systemic disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Nonalcoholic Steatohepatitis is a subtype of NAFLD (Nonalcoholic Fatty Liver disease) that is characterized...
Read More...
Feb 27, 2024
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial; Dupixent sBLA Accepted for FDA Priority Review; Biogen’s QALSODY Received Positive Opinion from CHMP; FDA Granted Orphan Drug Designation to Immune-Onc’s IO-202; Artiva Biotherapeutics’s AlloNK® in Lupus Nephritis
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...
Read More...
Feb 27, 2019
A helping hand in treatment of CRC
Patients suffering from Colorectal Cancer (CRC) usually gets affected with distant organ metastases spreading the tumor to other parts of the body. Patients with unresectable or borderline resectable Colorectal liver metastases (CRLM) are given Neoadjuvant Chemotherapy (NC) to limit liver resection and to lower dow...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
